CART-EGFRvIII + Pembrolizumab in GBM

NCT03726515 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: CART-EGFRvIII T cells
BIOLOGICAL: Pembrolizumab

Sponsor

University of Pennsylvania